Kenvue Inc. (NYSE:KVUE) Given Consensus Rating of “Hold” by Analysts

Shares of Kenvue Inc. (NYSE:KVUE) have earned an average recommendation of “Hold” from the sixteen analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $21.1786.

A number of equities analysts have issued reports on KVUE shares. UBS Group lowered their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th. Royal Bank Of Canada decreased their target price on Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. Rothschild Redb upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. Canaccord Genuity Group decreased their target price on Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Barclays cut their price objective on Kenvue from $20.00 to $17.00 and set an “equal weight” rating for the company in a report on Wednesday, October 1st.

Kenvue Price Performance

Shares of KVUE opened at $14.96 on Tuesday. Kenvue has a 12-month low of $14.05 and a 12-month high of $25.17. The business has a 50-day simple moving average of $18.42 and a two-hundred day simple moving average of $20.97. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The stock has a market cap of $28.71 billion, a PE ratio of 20.22, a PEG ratio of 2.20 and a beta of 0.72.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. During the same quarter in the prior year, the firm earned $0.32 EPS. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts anticipate that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.5%. The ex-dividend date was Wednesday, August 13th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is currently 112.16%.

Hedge Funds Weigh In On Kenvue

A number of hedge funds and other institutional investors have recently modified their holdings of KVUE. Pittenger & Anderson Inc. purchased a new position in shares of Kenvue in the 1st quarter worth about $30,000. Trust Co. of Vermont boosted its holdings in Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after acquiring an additional 1,150 shares during the period. TruNorth Capital Management LLC purchased a new stake in Kenvue during the 1st quarter valued at about $36,000. Truvestments Capital LLC purchased a new stake in Kenvue during the 1st quarter valued at about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its holdings in Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after acquiring an additional 1,287 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.